@article{10902/32975,
year = {2024},
url = {https://hdl.handle.net/10902/32975},
abstract = {Eptinezumab, a monoclonal antibody that targets calcitonin gene-related peptide (CGRP), was recently approved in Europe for the prophylactic treatment of migraine in adults who have at least four migraine days a month. Eptinezumab is administered by intravenous infusion every 12 weeks. During recent months, a considerable amount of evidence from eptinezumab trials has been published. The aim of this review is to describe the existing evidence on the tolerability, safety and efficacy of eptinezumab in patients with migraine. Data from randomized (PROMISE-1, PROMISE-2, RELIEF and DELIVER) and open-label (PREVAIL) phase 3 clinical trials have demonstrated the favorable effect of eptinezumab in migraine symptoms from first day of treatment. These studies showed that eptinezumab results in an overall reduction in mean monthly migraine days (MMDs), increases in the ≥50% and ≥75% migraine responder rates (MRRs) and improvements in patient-reported outcome measures in both patients with episodic migraine (EM) and with chronic migraine (CM), including patients who failed previous preventive treatments. The RELIEF trial also showed that eptinezumab, within 2 h of administration, reduced headache pain, migraine-associated symptoms and acute medication use when administered during a migraine attack. Eptinezumab benefits manifested as early as day 1 after dosing and with the subsequent doses lasted up to at least 2 years. Treatment-emergent adverse events reported by ≥2% of patients included upper respiratory tract infection and fatigue. Current evidence demonstrates that eptinezumab has a potent, fast-acting, sustained migraine preventive effect in patients with EM and CM. Eptinezumab has also shown to be well tolerated, supporting its use in the treatment of patients with migraine and inclusion in the current migraine therapeutic},
organization = {Funding: The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Medical writing was funded by Lundbeck Spain in accordance with Good Publication Practice (GPP3) guidelines. Lundbeck Spain was not involved in the study design, collection, analysis, interpretation of data, or the decision to submit it for publication. 
Acknowledgments: The authors thank Laura Prieto del Val of Evidenze Health España, S.L.U, for providing medical writing support (writing of the original draft, implementing changes in the manuscript after authors’ revisions, adapting the manuscript to journal requirements and submission to the journal), which was funded by Lundbeck Spain in accordance with Good Publication Practice (GPP3) guidelines.},
publisher = {Frontiers Media S.A.},
publisher = {Frontiers in Neurology, 2024,  15, 1355877},
title = {Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review},
author = {Irimia, Pablo and Santos-Lasaosa, Sonia and Pozo-Rosich, Patricia and Leira, Rogelio and Pascual Gómez, Julio and Láinez, José Miguel},
}